has acquired
                    a subsidiary of BICO Group AB
July 2025
William Blair acted as financial advisor to Sartorius AG in connection with its acquisition of MatTek, a subsidiary of BICO Group AB.
Read more
                Director, Medical Technology

Markus Mueller is a director for William Blair based in the firm’s Frankfurt office. He joined William Blair’s investment banking team in 2021. Prior to William Blair, he worked for BDT & Company and Rothschild & Co.
                    has acquired
                    a subsidiary of BICO Group AB
July 2025
William Blair acted as financial advisor to Sartorius AG in connection with its acquisition of MatTek, a subsidiary of BICO Group AB.
Read more
                    has partnered with
                    April 2025
William Blair acted as the exclusive M&A advisor to Armira on its partnership with Osypka AG.
Read more
                    a subsidiary of Sartorius AG
has merged with
                    July 2024
                    has acquired a majority stake in
                    July 2024
William Blair acted as the exclusive financial advisor to Novo Holdings in connection with its pending majority stake acquisition of Single Use Support.
Read more
                    has partnered with
                    April 2024
William Blair acted as the exclusive financial advisor to TT medic GmbH and its shareholders in connection with entering a partnership with Trill Impact.
Read more
                    has been acquired by
                    April 2023
                    has acquired
                    July 2023
William Blair acted as the exclusive financial advisor to Sartorius Group (XTRA:SRT) on its pending acquisition of Polyplus, for €2.4 billion, via its subsidiary Sartorius Stedim Biotech.
Read more
                    has subscribed to a directed share issue of
                    December 2022
                    has been acquired by
                    October 2022
William Blair acted as the exclusive financial advisor to CEVEC Pharmaceuticals in connection with its sale to Danaher Corporation (NYSE: DHR) and its portfolio company Cytiva.
Read more
                    a portfolio company of International Chemical Investors Group
has been acquired by
                    August 2022
William Blair acted as the exclusive financial advisor to International Chemical Investors Group in connection with its pending sale of its portfolio company, CordenPharma, to Astorg.
Read moreOur investment bankers are 100 percent committed to your organization’s sustained success. By drawing on our deep industry and product experience as well as our dedicated global resources, we provide advisory and financing services that allow you to capitalize on today’s opportunities and anticipate tomorrow’s challenges.
More about investment banking at William Blair
    William Blair’s Medical Technology team works with many of the world’s most innovative medical technology companies to help transform their growth trajectory through capital access and M&A partnerships. By combining deep expertise in the mega trends driving life science and medical product innovation and our knowledge of the regulatory and reimbursement environment, we deliver trusted advice and outstanding execution for market-leading companies and financial sponsors.
Learn more about our medical technology expertise
    William Blair is a premier global partnership with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
Year William Blair was founded
Employees worldwide
Client assets
Independent and employee-owned
Offices worldwide
Companies under coverage
As of September 30, 2025
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
This content is for informational and educational purposes only and not intended as investment advice or a recommendation to buy or sell any security. Investment advice and recommendations can be provided only after careful consideration of an investor's objectives, guidelines, and restrictions.
Copyright © 2025 William Blair & Company, L.L.C. | Privacy Terms
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures